Homology Medicines, Inc. QTTB 深 滬
等待開盤 01-29 09:30:00 美东时间
3.95
-0.040
-1.00%
華盛通- 最 高3.97
- 今 開3.95
- 成交量 18.82万股
- 最 低 3.65
- 昨 收 3.99
- 總市值 4860.24万
- 52周最高 6.3699
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.345
- 委 比 60.34%
- 總股本 1230.44万
- 歷史最高 572.40
- 量 比 1.14
- 振 幅 8.02%
- 歷史最低 1.345
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Market-Moving News for December 1st
QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties DYAI: 35% | Dyadic
2025-12-01 20:37
Q32 Bio Q3 EPS $(0.60) Beats $(0.99) Estimate
Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.99) by 39.39 percent. This is a 58.9 percent increase over losses of $(1.46) per share from the same
2025-11-13 20:01
美联储降息再迎大消息，纳指生科创年内新高，纳指生物科技ETF(513290)强势收涨6.22%，连续16日获资金加仓，“吸金”近7300万元
隔夜（10月8日）美股收盘，美股三大指数涨跌不一，纳指涨1.12%，标普500指数涨0.58%，两者均创收盘新高，道指收平。纳斯达克生物科技指数收涨0.89%...
2025-10-09 17:58
Q32 Bio Q2 EPS $(0.78) Beats $(1.29) Estimate
Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(1.29) by 39.53 percent. This is a 45.07 percent increase over losses of $(1.42) per share from the same
2025-08-06 20:37
Q32 Bio GAAP EPS of -$0.78
Q32 Bio press release (NASDAQ:QTTB): Q2 GAAP EPS of -$0.78. Cash and cash equivalents were $54.8 million as of June 30, 2025. Q32 Bio believes its cash and cash equivalents are sufficient to fund oper...
2025-08-06 19:45
Q32 Bio names interim chief medical officer
Clinical-stage biotechnology company Q32 Bio (NASDAQ:QTTB) appointed Adrien Sipos, M.D., Ph.D., as interim chief medical officer. Dr. Sipos succeeds Jason Campagna, M.D., Ph.D., who will be departin...
2025-06-25 19:52
Q32 Bio Board Member Mark Iwicki Resigns
The latest announcement is out from Q32 Bio ( ($QTTB) ). On April 25, 2025, Mar...
2025-04-26 04:35
美股大行评级 | 花旗：首予BioNTech SE(BNTX)"买入"评级，目标价145美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107226114384474112.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Zevra Therapeutics(ZVRA)"买入"评级，目标价从23美元升至25美元</p> <p>• Benchmark：维持E W Scripps(SSP)"买入"评级，目
2025-03-14 09:45
美股大行评级 | 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106863358302064640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元</p> <p>• HC Wainwright & Co.：维持LifeMD(LFMD)"买入"评级，目
2025-03-13 09:38
美股大行评级 | 潜在涨幅119%！Compass医疗获杰富瑞升目标价至8美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1096354625327304705.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Jones Trading：上调In8bio(INAB)评级至"买入"，目标价1.2美元</p> <p>• 丰业银行：维持INmune Bio(INMB)"跑赢大市"评级，目标价从22美元升至23美元</p> <p>•
2025-02-12 09:54
